Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Co., Ltd.
This is a multicenter, single-arm, open label, Phase 2 to evaluate efficacy, safety, pharmacokinetics and immunogenicity of E7777 in participants with relapsed or refractory PTCL and CTCL.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Participants who have histological diagnosis as peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
2. Participant who have measurable disease.
3. Participant who had previous systemic chemotherapy.
4. Participant who had disease progression (PD) or did not have response (complete response (CR) or partial response (PR)) in systemic chemotherapy, or relapsed or progressed after systemic chemotherapy.
5. Participant with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
6. Participant with adequate renal, liver and bone marrow function.
7. Male and female participants ≥20 years of age at the time of informed consent.
8. Participants who have provided written consent to participate in the study.
You may not be if
1. Participant with serious complications or histories.
2. Participant with history of hypersensitivity to protein therapeutics.
3. Participant who is positive for Human immunodeficiency virus (HIV) antibody, Hepatitis C virus (HCV) antibody, or Hepatitis B Surface (HBs) antigen.
4. Participant with malignancy of activity other than PTCL or CTCL within 36 months before informed consent.
5. Women of childbearing potential or man of impregnate potential who don't agree to use a medically effective method for contraception.
6. Woman who is pregnant or lactating.
7. Participant with allogeneic stem cell transplantation.
8. Participant who were decided as inappropriate to participate in the study by the investigator or sub-investigator.
Clareo Health | Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
